Monday, October 26, 2026

Semiconductors Surge 5% While Software Slides: Sector Rotation Confirmed

Micron and Dell each gained 5% on June 25 as semiconductor and HPC infrastructure stocks rallied while enterprise software and AI services fell. The Nasdaq Composite declined even as semis surged, ruling out broad risk-on sentiment and confirming capital is rotating from the AI application layer into picks-and-shovels hardware. Intel added 3.8%, SanDisk rose 4%, and KLA and Penguin Solutions each climbed 2.4%.

LM Salvado
LM Salvado

June 25, 2026

Semiconductors Surge 5% While Software Slides: Sector Rotation Confirmed
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Micron and Dell each gained 5% on June 25 while enterprise software and AI services stocks fell, confirming a sector rotation into semiconductor and HPC infrastructure.SanDisk added 4%.1 The Nasdaq Composite fell even as semiconductors rallied — a divergence that rules out broad risk appetite as the driver.

Infrastructure Over Application

Capital is moving from the AI application and software layer into picks-and-shovels hardware. Chips, memory, servers, and storage are gaining. Enterprise software vendors and AI services companies are losing.

The shift reflects a recalibration in how investors price the AI cycle. Early enthusiasm elevated software and services stocks on expectations of fast AI-driven revenue. That thesis is under pressure. Demand for physical infrastructure — chips, memory, compute — keeps growing regardless of which application-layer companies ultimately win.

Winners and Losers

Memory leads the winners: Micron and SanDisk both surged.1 Dell's gains reflect continued enterprise server and HPC demand. KLA benefits as semiconductor equipment spending holds. Penguin Solutions, a high-performance computing infrastructure provider, rose alongside the group.

On the losing side: enterprise software vendors and AI services firms dependent on corporate IT budget cycles. Enterprise spending remains constrained, squeezing companies that monetize AI at the application layer rather than supplying the hardware beneath it.

What Comes Next

The rotation is projected to persist over the next three to six months.1 Semiconductor ETFs and AI data center REITs are positioned to outperform if the trend holds. Fintech AI vendors tied to enterprise spending face continued pressure.

The Nasdaq's decline despite semiconductor strength is the defining signal. This is not a market-wide rally — it is a reallocation within tech. Money is moving from software to silicon, not flowing into the sector broadly.

For traders, the implication is straightforward: hardware-adjacent positions outperform while enterprise software lags until corporate spending cycles improve.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com